Home/Pipeline/IVL-003

IVL-003

Neurological Disorders

DiscoveryActive

Key Facts

Indication

Neurological Disorders

Phase

Discovery

Status

Active

Company

InVirtuoLabs

About InVirtuoLabs

InVirtuoLabs is a private, pre-clinical stage biotech leveraging a proprietary AI and simulation platform to accelerate drug discovery. The company operates a hybrid business model, developing its own internal pipeline of drug candidates while also engaging in co-development partnerships with pharmaceutical companies. With a seasoned leadership team and recognition from Swiss innovation programs, InVirtuoLabs aims to reduce the time, cost, and failure rates associated with traditional drug development.

View full company profile

Therapeutic Areas

Metabolic Disorders Neurological Disorders Pulmonary Vascular Disorders

Other Neurological Disorders Drugs

Drug	Company	Phase	Status
Biomarker Development Program	NeuroVision Imaging	Research	Active
GlyT2 Inhibitor Program	Micar Innovation	Discovery	Active
Biomarker Discovery & Validation Services	NeuroDex	Service	Active
Clinical Trial Biomarker Support	NeuroDex	Service	Active
CNS-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-002	InVirtuoLabs	Discovery	Active
Neurology Diagnostics Program	Aptus Biosciences	Discovery	Active
GM1 Ganglioside-based Therapies	TRB Chemedica International	Commercial / Development	Active
Undisclosed Neurology Programs	BridGene Biosciences	Discovery	Active
iPSC Platform Programs	Evotec	Preclinical Research	Active
ExacTcell Platform	Tevogen Bio	Discovery/Preclinical	Research